Vectura Group PLC (VEC) Earns “Buy” Rating from Panmure Gordon
Several other analysts have also issued reports on the stock. Numis Securities Ltd dropped their price target on shares of Vectura Group PLC from GBX 205 ($2.70) to GBX 170 ($2.24) and set a buy rating on the stock in a research report on Thursday. Shore Capital reissued a buy rating on shares of Vectura Group PLC in a research report on Thursday. Peel Hunt reissued a hold rating and issued a GBX 160 ($2.10) price objective on shares of Vectura Group PLC in a research report on Tuesday, October 31st. J P Morgan Chase & Co dropped their price objective on shares of Vectura Group PLC from GBX 210 ($2.76) to GBX 180 ($2.37) and set an overweight rating on the stock in a research report on Thursday, September 21st. Finally, Citigroup Inc. decreased their price target on shares of Vectura Group PLC from GBX 200 ($2.63) to GBX 180 ($2.37) and set a buy rating on the stock in a research note on Monday, September 18th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the stock. The company has an average rating of Buy and a consensus target price of GBX 189.67 ($2.49).
Shares of Vectura Group PLC (LON VEC) opened at GBX 90 ($1.18) on Thursday. Vectura Group PLC has a 1 year low of GBX 86.50 ($1.14) and a 1 year high of GBX 166.97 ($2.20).
ILLEGAL ACTIVITY WARNING: This article was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/11/13/vectura-group-plc-vec-earns-buy-rating-from-panmure-gordon.html.
About Vectura Group PLC
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Stock Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related stocks with our FREE daily email newsletter.